Literature DB >> 24144311

Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?

Frank Firkin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24144311     DOI: 10.3109/10428194.2013.856429

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Treatment for relapsed acute promyelocytic leukemia.

Authors:  Masamitsu Yanada
Journal:  Ann Hematol       Date:  2022-08-16       Impact factor: 4.030

2.  Real-world data on the dose-related effect of arsenic trioxide in the relapse of acute promyelocytic leukemia.

Authors:  Sha Gong; Huaiyu Wang; Huiyun Zhang; Wei Liu; Xinxin Zhang; Chenyang Zhao
Journal:  Mol Clin Oncol       Date:  2020-10-26

3.  Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.

Authors:  Bin Liang; Zhouyi Zheng; Yifen Shi; Jingjing Chen; Xudong Hu; Honglan Qian; Zhijian Shen; Songfu Jiang; Kang Yu; Jianhua Feng
Journal:  Onco Targets Ther       Date:  2017-04-26       Impact factor: 4.147

4.  Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.

Authors:  Li Zhang; Yao Zou; Yumei Chen; Ye Guo; Wenyu Yang; Xiaojuan Chen; Shuchun Wang; Xiaoming Liu; Min Ruan; Jiayuan Zhang; Tianfeng Liu; Fang Liu; Benquan Qi; Wenbin An; Yuanyuan Ren; Lixian Chang; Xiaofan Zhu
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.